A serendipitously identified novel small molecule procoagulant compound giving rise to a high-throughput screening assay based on human plasma.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Thrombosis Research

• Publication date

  2013-08-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.thromres.2013.05.023PMID 23830061
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Studies on the mechanism of action of the aptamer BAX499, an inhibitor of tissue factor pathway inhibitor.

  2012cited by this paper
• Polyphosphate: an ancient molecule that links platelets, coagulation, and inflammation.

  2012cited by this paper
• Aptamer ARC19499 mediates a procoagulant hemostatic effect by inhibiting tissue factor pathway inhibitor.

  2011cited by this paper
• Activated protein C inhibitor for correction of thrombin generation in hemophilia A blood and plasma 1

  2011cited by this paper
• Haemophilia: provision of factors and novel therapies: World Federation of Hemophilia goals and achievements

  2011cited by this paper
• Polyphosphate binds with high affinity to exosite II of thrombin

  2010cited by this paper
• Impact of Thrombogenic Mutations on Clinical Phenotypes of von Willebrand Disease

  2010cited by this paper
• Joint outcomes in patients with haemophilia: the importance of adherence to preventive regimens

  2009cited by this paper
• Novel trends in high-throughput screening.

  2009cited by this paper
• Multiple gene interaction and modulation of hemostatic balance

  2009cited by this paper
• Efficacy and safety of a new-class hemostatic drug candidate, AV513, in dogs with hemophilia A.

  2008cited by this paper
• Identification of promiscuous small molecule activators in high-throughput enzyme activation screens.

  2008influential reference
• Heparin is procoagulant in the absence of antithrombin

  2008cited by this paper
• Bivalent binding to gammaA/gamma'-fibrin engages both exosites of thrombin and protects it from inhibition by the antithrombin-heparin complex.

  2008cited by this paper
• Bivalent Binding to γA/γ′-Fibrin Engages Both Exosites of Thrombin and Protects It from Inhibition by the Antithrombin-Heparin Complex*

  2008cited by this paper
• Plasma fibrinogen γ′ chain content in the thrombotic microangiopathy syndrome

  2007cited by this paper
• Plasma fibrinogen gamma' chain content in the thrombotic microangiopathy syndrome.

  2007cited by this paper
• Crystal structure of thrombin in complex with fibrinogen gamma' peptide.

  2006cited by this paper
• Low molecular weight activated protein C inhibitors as a potential treatment for hemophilic disorders.

  2006cited by this paper
• Peptidomimetic inhibitors for activated protein C: implications for hemophilia management

  2006cited by this paper
• Molecular recognition mechanisms of thrombin

  2005cited by this paper
• Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B

  2005cited by this paper
• Improved coagulation in bleeding disorders by Non-Anticoagulant Sulfated Polysaccharides (NASP)

  2005cited by this paper
• Genetic variation in the fibrinogen gamma gene increases the risk for deep venous thrombosis by reducing plasma fibrinogen gamma' levels.

  2005cited by this paper
• Blood coagulation kinetics: high throughput method for real-time reaction monitoring

  2004cited by this paper
• The hemostatic agent ethamsylate promotes platelet/leukocyte aggregate formation in a model of vascular injury

  2004cited by this paper
• Treatment of von Willebrand's Disease.

  2004cited by this paper
• Calibrated Automated Thrombin Generation Measurement in Clotting Plasma

  2003cited by this paper
• Tranexamic acid: a review of its use in surgery and other indications.

  1999cited by this paper
• Selection of a RNA aptamer that binds to human activated protein C and inhibits its protease function.

  1998cited by this paper
• Treatment of von Willebrand's disease

  1997cited by this paper
• Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years.

  1997cited by this paper
• Thrombus Weight as a Measure of Hypercoagulability Induced by Drugs

  1979cited by this paper

• Small-molecule modulators of serine protease inhibitor proteins (serpins).

  2020cites this paper
• Untangling the complexity of blood coagulation network: use of computational modelling in pharmacology and diagnostics

  2016cites this paper